CoChat

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Open access
Sun, Lei, Zheng, Zhi-Ming, Shao, Chang-Sheng, Zhang, Zhi-Yong, Li, Ming-Wei, Wang, Li, Wang, Han, Zhao, Gen-Hai, Wang, Peng · 2022 · Pharmaceuticals

Published version of a preprint

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes. Therefore, improving GLP-1 receptor agonist (GLP-1RA) stability is a major obstacle for drug development. We analyzed human GLP-1, DPP-4, and GLP-1 receptor structures and designed three GLP-1RAs, which were introduced into fusion protein fragments and changed in the overall conformation. This modification effectively prevented GLP-1RAs from entering the DPP-4 active center without affecting GLP-1RAs’ ability to bind to GLP-1R, the new GLP-1RA hypoglycemic effect lasting for >24 h. Through molecular modeling, molecular dynamics calculation, and simulation, possible tertiary structure models of GLP-1RAs were obtained; molecular docking with DPP-4 and GLP-1R showed access to the fusion protein. The overall conformational change of GLP-1RAs prevented DPP-4 binding, without affecting GLP-1RAs’ affinity to GLP-1R. This study provides important drug design ideas for GLP-1RA development and a new example for application of structural biology-based protein design in drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15060740

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure A1 Analysis on the MD trajectory of Model3. (a) The time evolution of RMSD and (b) RMSF of residues. Both RMSD and RMSF were calculated using all the Cα atoms.
Figure A1 Analysis on the MD trajectory of Model3. (a) The time evolution of RMSD and (b) RMSF of residues. Both RMSD and RMSF were calculated using all the Cα atoms.CC BY · PubMed Central
Figure 1 Sequences of GLP-1Rs (G1, G2, G4), β sheet is the antiparallel β lamellar domain added on N-terminal or C-terminal.
Figure 1 Sequences of GLP-1Rs (G1, G2, G4), β sheet is the antiparallel β lamellar domain added on N-terminal or C-terminal.CC BY · PubMed Central
Figure 2 GLP-1RAs preparation. The refolding, digestion and purification processes were monitored by LC-MS, and the results of each GLP-1RAs obtained after purification were as follows: (a) G1 MW: 8212.4 Da; (b) G2 MW: 8210.4 Da; (c) G4 MW: 7826.0 Da.
Figure 2 GLP-1RAs preparation. The refolding, digestion and purification processes were monitored by LC-MS, and the results of each GLP-1RAs obtained after purification were as follows: (a) G1 MW: 8212.4 Da; (b) G2 MW: 8210.4 Da; (c) G4 MW: 7826.0 Da.CC BY · PubMed Central
Figure 3 Affinity between GLP-1 receptor and (a) GLP-1; (b) G1; (c) G2; (d) G4.
Figure 3 Affinity between GLP-1 receptor and (a) GLP-1; (b) G1; (c) G2; (d) G4.CC BY · PubMed Central
Figure 4 DPP-4 digestion curve. See also Table A1: Area Under Curve of DPP-4 digestion.
Figure 4 DPP-4 digestion curve. See also Table A1: Area Under Curve of DPP-4 digestion.CC BY · PubMed Central
Figure 5 Glucose tolerance test of GLP-1RAs. (a) Blood glucose curve on the first day. (b) Blood glucose AUC on the first day. (c) Blood glucose curve on the second day. (d) Blood glucose AUC on the second day. See also Table A3: “The first day’s Glucose tolerance test results” and Table A4: “The second day’s Glucose tolerance test results”.
Figure 5 Glucose tolerance test of GLP-1RAs. (a) Blood glucose curve on the first day. (b) Blood glucose AUC on the first day. (c) Blood glucose curve on the second day. (d) Blood glucose AUC on the second day. See also Table A3: “The first day’s Glucose tolerance test results” and Table A4: “The second day’s Glucose tolerance test results”.CC BY · PubMed Central
Figure 6 G1 modeling structure (Model3).
Figure 6 G1 modeling structure (Model3).CC BY · PubMed Central
Figure 7 Molecular docking structures. (a) GLP-1 and DPP-4 molecule complex. (b) G1 and DPP-4 molecule complex. (c) GLP-1 and GLP-1R complex. (d) G1 and GLP-1R complex. The DPP-4, GLP-1, and G1 GLP-1R are colored by gray, orange, yellow and sliver, respectively. In DPP-4, the represented active residues GLU205, GLU206, SER630 and HIS740 are colored by blue, red, lime and purple, respectively. In GLP-1, the represented active residues GLN17, LYS20 and TRP25 are colored by pink, lime and black, respectively. In GLP-1R, the represented active residues LEU32, TRP39, LEU123, GLU127 and GLU128 are colored by blue, orange, cyan, green and red, respectively. The represented active residues are highlighted by CPK model, and other active residues are showed by New Cartoon model.
Figure 7 Molecular docking structures. (a) GLP-1 and DPP-4 molecule complex. (b) G1 and DPP-4 molecule complex. (c) GLP-1 and GLP-1R complex. (d) G1 and GLP-1R complex. The DPP-4, GLP-1, and G1 GLP-1R are colored by gray, orange, yellow and sliver, respectively. In DPP-4, the represented active residues GLU205, GLU206, SER630 and HIS740 are colored by blue, red, lime and purple, respectively. In GLP-1, the represented active residues GLN17, LYS20 and TRP25 are colored by pink, lime and black, respectively. In GLP-1R, the represented active residues LEU32, TRP39, LEU123, GLU127 and GLU128 are colored by blue, orange, cyan, green and red, respectively. The represented active residues are highlighted by CPK model, and other active residues are showed by New Cartoon model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 17

Metadata

Authors
Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P.
Affiliations
  • University of Science and Technology of China (CN)
  • Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China
  • MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, National Science Center for Physical Sciences at Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230022, China
  • Chinese Academy of Sciences (CN)
Corresponding author
Wang, Peng
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-06-13
Volume
15
Issue
6
Pages
740
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4282831524
Cited by
17
References
53
Citations by year
2026: 8 · 2025: 5 · 2024: 2 · 2023: 2
FWCI
1.67
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Major Projects of Science and Technology of Anhui Province (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
  • China National Key Research and Development Program (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
  • Development Plan of Anhui Province (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
  • National Natural Science Foundation of China (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
GLP-1 receptor agonists, glucagon-like peptide-1, dipeptidyl peptidase IV, type 2 diabetes, antidiabetic drugs, drug stability, fusion protein, conformational change, ligand-receptor interactions, long-acting drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.